Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer
NCT05274048Phase 1Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neratinib and trastuzumab deruxtecan in gastric cancer (GC), esophageal cancer and gastrointestinal cancer, sponsored by Fox Chase Cancer Center. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase II Dose at 2 years. Started Jun 2022; status: recruiting.
02
Drugs
neratinibtrastuzumab deruxtecan
03
Conditions
gastric cancer (GC)esophageal cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT05274048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274048.